Hemady
Multiple Myeloma
ApprovedCommercial
Key Facts
About Dexcel Pharma USA
Dexcel Pharma USA is the U.S. subsidiary of Israel's largest private pharmaceutical company, Dexcel Pharma, established following the 2022 acquisition of Edenbridge Pharmaceuticals and a 2024 rebranding. The company commercializes a portfolio of generic, branded, and specialty products, with a strategic focus on complex conditions like multiple myeloma and Gaucher disease. It leverages its parent company's global R&D and manufacturing scale to provide affordable, high-quality medications, positioning itself as a trusted partner in the U.S. generic and specialty pharmaceutical market.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| AV-353 | AVEO Oncology | Pre-clinical |
| Sequesta™ | ID4Pharma | Pre-clinical |